Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Short Interest Update

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) was the recipient of a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 7,748 shares, a growth of 94.0% from the June 15th total of 3,994 shares. Approximately 1.5% of the company’s shares are short sold. Based on an average daily volume of 35,104 shares, the short-interest ratio is currently 0.2 days.

Eloxx Pharmaceuticals Trading Down 4.5%

Eloxx Pharmaceuticals stock traded down $0.57 during trading on Thursday, hitting $12.02. The company had a trading volume of 48,923 shares, compared to its average volume of 21,495. The stock has a market cap of $8.29 million, a PE ratio of -0.79 and a beta of -1,891.27. Eloxx Pharmaceuticals has a 1-year low of $11.41 and a 1-year high of $17.50. The company has a 50 day simple moving average of $17.45.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.